Top 10 Companies in the Southeast Asia Angiographic Entry Needles Market (2026): Market Leaders Powering Regional Growth

MARKET INSIGHTS

The Southeast Asia angiographic entry needles market size was valued at USD 42.8 million in 2024. The market is projected to grow from USD 46.1 million in 2025 to USD 78.9 million by 2034, exhibiting a CAGR of 7.3% during the forecast period.

Angiographic entry needles are specialized medical devices used for vascular access during angiography procedures. These sterile, single‑use needles facilitate precise puncture of blood vessels for contrast media injection, featuring either winged or non‑winged designs with various gauge sizes. The product category plays a critical role in diagnostic and interventional cardiology procedures across Southeast Asia’s growing healthcare infrastructure.

Market growth is being driven by increasing cardiovascular disease prevalence, with the region seeing a 28% rise in cardiac procedures between 2020‑2024. Furthermore, government healthcare modernization initiatives and expanding catheterization laboratories across Thailand, Malaysia, and Vietnam are creating new demand. Recent technological advancements, including ultrasound‑guided vascular access systems, are further propelling adoption rates in premium hospital settings.

Southeast Asia Angiographic Entry Needles Market – View in Detailed Research Report

Top 10 Companies in the Southeast Asia Angiographic Entry Needles Market (2026)

1. Boston Scientific

Headquarters: Boston, USA

Key Offering: Winged and wing‑less angiographic entry needles integrated with advanced imaging suites.

Boston Scientific’s Singapore‑based manufacturing hub supplies a full spectrum of needles that combine ergonomic design with precision engineering, enabling rapid vessel access and reducing procedural time. The company’s focus on high‑performance materials and surface coatings aligns with the increasing demand for low‑trauma, high‑accuracy devices in both public and private hospitals.

Sustainability & Growth Initiatives:

• Investment in additive manufacturing to reduce lead times.
• Partnerships with regional distributors to expand market reach.
• Commitment to circular supply chains through reusable packaging components.

2. Terumo Corporation

Headquarters: Tokyo, Japan

Key Offering: Flexible, pediatric‑grade angiographic entry needles with enhanced tip navigation.

Terumo’s Thailand production line focuses on needles that provide superior flexibility and tip control, essential for complex vascular procedures. The company’s collaboration with local hospitals ensures that product development is closely aligned with clinical needs, driving adoption among interventional radiologists.

Sustainability & Growth Initiatives:

• Development of biodegradable coatings to minimize environmental impact.
• Expansion of local assembly to reduce import dependency.
• Support for training programs in emerging markets.

3. Medtronic

Headquarters: Dublin, Ireland

Key Offering: Integrated needle systems that pair with Medtronic’s catheter technology.

Medtronic’s Singapore facility delivers needles that are engineered for seamless integration with its catheter platforms, offering clinicians a unified workflow. The company’s emphasis on data‑driven product refinement helps maintain competitive advantage in a rapidly evolving market.

Sustainability & Growth Initiatives:

• Investment in digital supply‑chain analytics.
• Partnerships with national health ministries for streamlined approvals.
• Commitment to reducing single‑use plastic waste.

4. Philips Healthcare

Headquarters: Amsterdam, Netherlands

Key Offering: Advanced imaging‑compatible angiographic entry needles with real‑time feedback.

Philips’s Singapore and Malaysia plants produce needles that integrate with Philips’ imaging platforms, providing clinicians with enhanced visibility and precision. The company’s focus on user‑centric design has led to widespread adoption in high‑volume tertiary centers.

Sustainability & Growth Initiatives:

• Development of low‑energy consumables.
• Collaboration with hospitals on waste‑management programs.
• Investment in AI‑driven procedural analytics.

5. B. Braun Melsungen AG

Headquarters: Melsungen, Germany

Key Offering: Premium‑grade angiographic needles with advanced coating technology.

B. Braun’s Singapore facility supplies needles that deliver high reliability and consistency, supporting a range of interventional procedures. The company’s strong relationships with hospital groups enable it to capture premium market segments where performance and durability are paramount.

Sustainability & Growth Initiatives:

• Implementation of green manufacturing practices.
• Expansion of local supply chains to reduce carbon footprint.
• Support for clinical trials focused on needle safety.

6. Becton‑Dickinson (BD)

Headquarters: Franklin Lakes, USA

Key Offering: Bundled needle kits designed for inventory efficiency.

BD’s Malaysia operations provide bundled kits that simplify inventory management for private networks. The company’s focus on modular packaging enhances supply‑chain resilience and supports rapid deployment in emerging markets.

Sustainability & Growth Initiatives:

• Development of recyclable packaging solutions.
• Partnerships with logistics providers to optimize delivery routes.
• Investment in training programs for clinicians.

7. Vygon

Headquarters: Paris, France

Key Offering: Low‑cost, single‑use angiographic needles for small clinics.

Vygon’s Vietnam facility supplies needles that meet the budget constraints of smaller clinics while maintaining essential safety standards. The company’s focus on affordability has driven widespread adoption in cost‑sensitive settings.

Sustainability & Growth Initiatives:

• Use of biodegradable materials in needle construction.
• Collaboration with local manufacturers to reduce shipping distances.
• Support for community‑based training initiatives.

8. Cardinal Health

Headquarters: Dublin, Ireland

Key Offering: Integrated needle kits with streamlined logistics.

Cardinal Health’s Malaysia operations focus on bundled solutions that reduce inventory complexity for private networks. The company’s emphasis on logistics efficiency supports rapid market penetration across diverse healthcare environments.

Sustainability & Growth Initiatives:

• Implementation of digital order‑to‑delivery tracking.
• Partnerships with regional distributors for last‑mile delivery.
• Investment in low‑energy manufacturing processes.

9. R.M. Instruments

Headquarters: Bangkok, Thailand

Key Offering: Innovative wing‑less angiographic needles tailored for regional needs.

R.M. Instruments is pursuing regulatory approvals for its wing‑less designs, positioning itself as a nimble alternative to larger suppliers. The company’s focus on local market knowledge and rapid product development has attracted interest from public‑sector hospitals.

Sustainability & Growth Initiatives:

• Use of locally sourced materials to reduce supply‑chain risk.
• Collaboration with universities on needle‑design research.
• Participation in government incentive programs for domestic manufacturing.

10. Axiom Medical

Headquarters: Manila, Philippines

Key Offering: Advanced wing‑less needles with optimized tip geometry.

Axiom Medical’s focus on wing‑less designs aligns with the growing preference for low‑profile devices that reduce tissue trauma. The company’s partnership with regional distributors has accelerated market adoption in both public and private sectors.

Sustainability & Growth Initiatives:

• Development of eco‑friendly coatings.
• Engagement with local health ministries for streamlined approvals.
• Investment in clinician training programs.

Download FREE Sample Report

Get Full Report

Outlook

The Southeast Asia angiographic entry needles market is poised for steady expansion as healthcare infrastructure continues to modernize. The convergence of regulatory standards and the adoption of minimally invasive imaging are expected to sustain demand growth, particularly in high‑volume tertiary centers and emerging private‑hospital networks. Companies that can combine product performance with cost‑efficiency and robust supply‑chain resilience will be best positioned to capture market share.

Future Trends

Key trends shaping the next decade include the shift toward wing‑less needle designs, the integration of ultrasound‑guided vascular access, and the rise of hybrid interventional suites that demand flexible, low‑profile devices. Manufacturers that invest in dual‑mode feedback technologies and collaborate closely with clinicians for real‑time data collection will likely lead the market. Additionally, regional investment incentives and public‑private partnerships are expected to accelerate the deployment of advanced needle solutions across Southeast Asia.